IT & Pharma Stocks: Are They Still the Best Long-Term Bets for Indian Investors in 2025?

Estimated Read Time: 4 minutes
Word Count: 500-600

IT & Pharma 

Are IT & Pharma Still Long-Term Bets?

For decades, IT services and pharmaceuticals have been the twin engines of India’s export growth story. Infosys, TCS, Wipro, HCL, Sun Pharma, Cipla, Dr. Reddy’s- these are some defensive stocks in India.

But in 2025, investors are asking:

• With a global slowdown, will demand shrink?
• With rupee-dollar swings, are earnings reliable?
• With rising regulation, can margins hold?

This blog gives you a DIY framework to decide whether IT & Pharma remain good long-term bets.

Global Slowdowns & Currency Moves in IT & Pharma

Impact of Global Slowdowns

• IT Sector:
  • 80%+ of revenue comes from US & Europe.
  • Slowdowns → delayed tech spending, fewer large deals.
  • But digital transformation, AI, and cloud remain secular drivers.
• Pharma Sector:
  • The US is the largest export market for Indian generics.
  • Recession = steady demand (medicine is non-discretionary).
  • Regulatory inspections (USFDA) are bigger risks than demand slowdown.

Impact of Currency (USD/INR)

• Rupee Depreciation: This is clearly positive for exporters as more INR per $ earned.
• Rupee Appreciation: Negative for exporters when the earnings translate into fewer rupees.
• Hedge Factor: Most IT vs Pharma investment companies hedge exposures, but currency still continues to drive quarterly volatility.

Lastly, IT is cyclical with slowdown risks and Pharma is defensive, resilient in slowdowns. Both benefit when INR weakens. That’s why they are considered the best IT stocks 2025 in India.

How do IT and Pharma Together Create a Stable Portfolio?

1. IT Sector — Digital Backbone

• India’s top IT giants are embedded in the digital strategies of Fortune 500.
• From Cloud and AI to automation and cybersecurity, promote secular growth themes.
• Near-term: Margins may increase if global clients cut their spending.
• Long-term: Secular demand remains strong → still a core India story.

2. Pharma Sector — Global Generics Leader

• India supplies ~20% of global generic medicines.
• With ageing populations and increasing healthcare demands, pharma is always on the verge of expansion.
• The real risk is the price erosion in US generics, compliance issues like FDA audits.
• But in the long-term, it still remains a defensive wealth stock.
• When brought together, IT & Pharma balance each other as IT is cyclical growth, Pharma is steady defensive.

 Key Metrics to Watch

For IT:

• Revenue Growth in Constant Currency (CC): Filters currency noise.
• Deal Wins (TCV): Strong pipeline = future growth visibility.
• Margin Trends: Watch EBIT margins — rising costs can squeeze.
• Attrition Rate: High attrition = wage inflation risk.

For Pharma:

• USFDA Approvals/Inspections: Positive = new product launches; negative = plant shutdowns.
• Revenue Mix: US generics vs domestic formulations.
• R&D Spend (% of sales): Higher = pipeline strength.
• Margins: Sustained 18–22% EBITDA margins = healthy.

Take the Charge: Do This

1. Diversify Within Sector Leaders
   • IT: Go for TCS, Infosys, HCL for stability; mid-tier. And choose LTIMindtree and Coforge for higher growth and scalability.
   • Pharma: Go for Sun Pharma, Cipla, Dr. Reddy’s for US scale while domestic-focused like Torrent for India play.
2. Track Currency & Policy
   • IT earnings track USD/INR moves.
   • Pharma valuations often swing on the FDA news- track regularly.
3. Use Sector Allocation Discipline
   • IT + Pharma together: 20–30% of the equity portfolio is reasonable.
   • Avoid overweighting either.
4. Invest via ETFs/Mutual Funds if Unsure
   • IT ETFs and Pharma funds give diversified exposure.
   • Good for DIY investors who don’t want stock-picking risk.

 Decision Guide

• If You Already Hold IT/Pharma:
  • Stay invested — these are structural sectors.
  • Trim only if allocation >30%.
• If You Don’t Hold Yet:
  • Enter gradually (SIPs in sector funds or staggered stock buys).
  • Don’t lump-sum during hype rallies.
• If You’re Overweight in Cyclicals (like Infra, Auto, PSU Banks):
  • Add Pharma as a defensive balance.
  • Add IT selectively for long-term growth.

 Example: Balanced Portfolio

• Investor A (Overconcentrated in IT):
  • 50% portfolio in Infosys, Wipro, TCS.
  • Global slowdown = portfolio drawdown 25%.
• Investor B (Balanced IT + Pharma):
  • 15% IT, 15% Pharma, 70% diversified equities.
  • Pharma cushions IT losses, portfolio stable.

 Lesson: Balance cyclical IT with defensive Pharma.

 Final Takeaway

Yes, IT & Pharma remain solid long-term bets — but not in isolation.

• IT = secular growth, cyclical risks.
• Pharma = defensive stability, regulatory risks.

Together, they form a balanced export-oriented pillar in your portfolio.

Open your FREE Wealth Alpha account. Upload holdings once, get instant portfolio scores, AI‑driven optimization, and pro screeners in one place. 

Sign up now: https://wealthalpha.in